According to the initial report pertaining the onx-aap post-market clinical follow-up study, "here are another group of adverse events to report.I had a meeting with the site today and they assured me that obtaining additional information /records/source documents will not likely occur at this time.They provided what information they could obtain and if nothing was reported, it was because no further information was available to them." event #1 [(b)(6) 2011]: subject aap- 025 on day 2 from aortic valve replacement, anemia associated is documented on crf.Subject is documented to have received a transfusion.No source/medical records are included and details are unknown.Subject ultimately discharged from hospital setting on post op day 22.Event #2 [(b)(6) 2011]: subject aap- 025 experienced tachy-brady syndrome on day 18 from aortic valve replacement while still hospitalized in the immediate post operative phase.Subject underwent insertion of dual chamber permanent pacemaker on same day and was ultimately discharged from acute hospital on day 22 post valve replacement.No source or medical records were provided.Event #3 [(b)(6) 2019]: subject aap- 025 was presented to emergency room on day 3059 with acute massive right sided subdural hematoma.Crf 5 indicates this is a major bleeding event.Inr at time of presentation was measured at 3.3.Subject underwent emergency hematoma evacuation/craniotomy.Subject ultimately expired on day 5 of the event.No source or medical records were provided.While performing crf review, noted aes had been documented- no medical records have been provided for review.Reported available information to field assurance.No additional information forthcoming.
|